Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of Bromantane and P21 — mechanism, dosing, side effects, legal status, and pricing.
Bromantane (Ladasten) is a synthetic adamantane-derivative small molecule — not a peptide — developed in Russia as an "actoprotector"/adaptogen with combined mild psychostimulant and anxiolytic activity. It is an approved prescription drug in Russia (Ladasten) for asthenic disorders, but it has no FDA or EMA approval and no blinded, placebo-controlled human trials. It is prohibited in sport (WADA S6 stimulant) and circulates on the gray market as a research chemical.
P21 (also P021) is a small peptidergic compound — the tetrapeptide core Asp-Gly-Gly-Leu with an N-terminal acetyl and a C-terminal adamantylated glycine amide (Ac-DGGL(A)G-NH2) — derived from an active region (residues ~148–151) of human ciliary neurotrophic factor (CNTF). It was designed and characterized in the Khalid Iqbal laboratory at the New York State Institute for Basic Research in Developmental Disabilities (NYS IBR). It is an experimental, preclinical compound — NOT FDA-approved and NOT tested in humans in published trials. Distinct from the cyclin-dependent kinase inhibitor protein p21/CDKN1A/WAF1 (a completely different gene product; the two share only the name).
Bromantane
P21
Category
Legal Status
Mechanism
Dose Range
Route
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
Bromantane
No pricing data yet.
Check Bromantane prices →P21
COA corpus from Disclosed Labs — independently tested batches only.
Bromantane
4
COAs
99.9%
Avg purity
3
Labs
P21
2
COAs
99.1%
Avg purity
1
Labs
Human evidence is limited to Russian clinical use of Ladasten. The largest published dataset is an open-label, non-comparative multicenter trial (28 centers, N=728) in asthenic disorder at 50–100 mg/day for 28 days (Voznesenskaia et al., 2010), reporting symptomatic improvement (CGI-S response 76.0%, CGI-I 90.8%) with adverse effects in ~3% of patients. No blinded, placebo-controlled randomized trial exists and there is no ClinicalTrials.gov registration. All mechanistic and toxicology data are preclinical (rat, mouse, in-vitro). Approved only in Russia; not FDA/EMA-approved; not a peptide.
Key references
Evidence is preclinical (rodent) only. Key publication: Kazim, Blanchard, Dai, Tung, LaFerla, Iqbal & Iqbal, Neurobiology of Disease 2014 (PMID 25046994) reported that chronic oral P021 rescued cognition, boosted dentate-gyrus neurogenesis, and reduced tau hyperphosphorylation in 3xTg-AD mice. Additional preclinical papers from the Iqbal group (and collaborators) have shown dendritic/synaptic rescue in AD and aging rodent models (e.g., Kazim et al., Alzheimer's Res Ther 2017). No Phase 1/2/3 human trials have been published; no human safety or pharmacokinetic data exist. Grey-market vendor material is unvalidated — purity, identity, and dosing are not verifiable.
Bromantane and P21 are both in the Cognitive category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Frequency
Dosing Notes
Side Effects
Contraindications
Lab Testing
Disclosed Labs